The estimated Net Worth of Andrew Hirsch is at least $1.3 Milion dollars as of 30 August 2023. Mr Hirsch owns over 7,500 units of C4 Therapeutics stock worth over $696,636 and over the last 8 years he sold CCCC stock worth over $0. In addition, he makes $607,958 as CEO a Pres & Director at C4 Therapeutics.
Sign up
Mr Hirsch CCCC stock SEC Form 4 insiders trading
Mr has made over 8 trades of the C4 Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of CCCC stock worth $45,000 on 30 August 2023.
The largest trade he's ever made was exercising 12,500 units of C4 Therapeutics stock on 30 January 2023 worth over $75,000. On average, Mr trades about 1,931 units every 42 days since 2016. As of 30 August 2023 he still owns at least 116,106 units of C4 Therapeutics stock.
You can see the complete history of Mr Hirsch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Andrew J. Hirsch biography
Andrew J. Hirsch is the CEO, Pres & Director at C4 Therapeutics.
What is the salary of Mr Hirsch?
As the CEO a Pres & Director of C4 Therapeutics, the total compensation of Mr Hirsch at C4 Therapeutics is $607,958. There are 1 executives at C4 Therapeutics getting paid more, with Dr. Adam S. Crystal M.D., Ph.D. having the highest compensation of $661,550.
How old is Mr Hirsch?
Mr Hirsch is 50, he's been the CEO a Pres & Director of C4 Therapeutics since . There are 3 older and 2 younger executives at C4 Therapeutics. The oldest executive at C4 Therapeutics, Inc. is Dr. Kenneth C. Anderson M.D., Ph.D., 70, who is the Co-Founder, Independent Director & Member of Scientific Advisory Board.
What's Mr Hirsch's mailing address?
Andrew's mailing address filed with the SEC is C/O EDITAS MEDICINE, INC.,, 11 HURLEY ST., CAMBRIDGE, MA, 02141.
Insiders trading at C4 Therapeutics
Over the last 4 years, insiders at C4 Therapeutics have traded over $12,678,122 worth of C4 Therapeutics stock and bought 27,275 units worth $336,287 . The most active insiders traders include Marc A Cohen, Alain J Cohen a Elena Prokupets. On average, C4 Therapeutics executives and independent directors trade stock every 17 days with the average trade being worth of $56,874. The most recent stock trade was executed by Andrew Hirsch on 30 August 2023, trading 7,500 units of CCCC stock currently worth $45,000.
What does C4 Therapeutics do?
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
What does C4 Therapeutics's logo look like?
Complete history of Mr Hirsch stock trades at Agios Pharmaceuticals Inc, Editas Medicine Inc a C4 Therapeutics
C4 Therapeutics executives and stock owners
C4 Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Adam S. Crystal M.D., Ph.D.,
Chief Medical Officer -
Andrew J. Hirsch,
CEO, Pres & Director -
Marc A. Cohen,
Co-Founder, Exec. Chairman & Sec. -
Dr. Kenneth C. Anderson M.D., Ph.D.,
Co-Founder, Independent Director & Member of Scientific Advisory Board -
Kristina Zambouras,
Director of HR -
Jolie M. Siegel J.D.,
Chief Legal Officer -
Kendra Adams,
Sr. VP of Communications & Investor Relations -
Dr. Stewart Fisher,
Chief Scientific Officer -
Lauren White,
Chief Financial Officer -
Dr. Nathanael S. Gray Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Adam Crystal,
Chief Medical Officer -
Jolie Siegel,
Chief Legal Officer -
Mark Mossler,
Chief Accounting Officer -
Stephen Fawell,
Director -
Laura Jean Wahlberg,
VP of Finance Corp Controller -
Leonard Reyno,
Chief Medical Officer -
Glenn Dubin,
Director -
Marc A Cohen,
Director -
Lauren White,
Chief Financial Officer -
Elena Prokupets,
Director -
Bruce Downey,
Director -
Malcolm Salter,
Director -
Kenneth Carl Anderson,
Director -
William Mckee,
Chief Financial Officer -
Stewart Fisher,
Chief Scientific Officer -
Alain J Cohen,
Director -
Donna Roy Grogan,
Director -
Laura Bessen,
Director -
Utpal Koppikar,
Director -
Scott N Boyle,
Chief Business Officer -
Kelly Schick,
Chief People Officer -
Owen Hughes,
Director -
Ronald Harold Wilfred Cooper,
Director